Patient and Physician Preferences for Front-Line Treatment of Advanced Stage Hodgkin Lymphoma in Germany, France and the United Kingdom

被引：0
|
作者：
Broeckelmann, Paul
Stamatoullas, Aspasia
McMullen, Suzanne
Wilson, Ben
Mueller, Kerstin
Goring, Sarah
Zagadailov, Erin
Gautam, Ashish
Huebner, Dirk
Dalal, Mehul
Illidge, Tim M.
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4082
引用
收藏
页数：4
相关论文
共 50 条
  • [41] Randomized Comparison of the Stanford V Regimen and ABVD in the Treatment of Advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244
    Hoskin, Peter J.
    Lowry, Lisa
    Horwich, Alan
    Jack, Andrew
    Mead, Ben
    Hancock, Barry W.
    Smith, Paul
    Qian, Wendi
    Patrick, Philippa
    Popova, Bilyana
    Pettitt, Andrew
    Cunningham, David
    Pettengell, Ruth
    Sweetenham, John
    Linch, David
    Johnson, Peter W. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (32) : 5390 - 5396
  • [42] An update of a phase II trial of CHOP followed by Tositumomab/Iodine 1-131 Tositumomab (Bexxar®) for front-line treatment of advanced stage, follicular lymphoma:: Southwest oncology group protocol 9911.
    Press, OW
    Unger, J
    Maloney, D
    Braziel, RM
    LeBlanc, M
    Grogan, T
    Miller, TP
    Fisher, RI
    BLOOD, 2005, 106 (11) : 107A - 107A
  • [43] High-dose therapy and autologous stem cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy: long-term results
    Carella, Angelo Michele
    Bellei, Monica
    Brice, Pauline
    Gisselbrecht, Christian
    Visani, Giuseppe
    Colombat, Philippe
    Fabbiano, Francesco
    Donelli, Amedea
    Luminari, Stefano
    Feugier, Pierre
    Browett, Peter
    Hagberg, Hans
    Federico, Massimo
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 (01): : 146 - 148
  • [44] Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma
    Esmaeli, B.
    McLaughlin, P.
    Pro, B.
    Samaniego, F.
    Gayed, I.
    Hagemeister, F.
    Romaguera, J.
    Cabanillas, F.
    Neelapu, S. S.
    Banay, R.
    Fayad, L.
    Saville, M. Wayne
    Kwak, L. W.
    ANNALS OF ONCOLOGY, 2009, 20 (04) : 709 - 714
  • [45] Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: Results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519)
    Johnson, PWM
    Radford, JA
    Cullen, MH
    Sydes, MR
    Walewski, J
    Jack, AS
    MacLennan, KA
    Stenning, SP
    Clawson, S
    Smith, P
    Ryder, D
    Hancock, BW
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (36) : 9208 - 9218
  • [46] Bortezomib (VELCADE), Rituximab, Cyclophosphamide, Dexamethasone (VRCD) Combination Therapy In Front-Line Low-Grade Non-Hodgkin Lymphoma (LG-NHL) Is Active In Elderly Patient Population
    Nabhan, Chadi
    Dalal, Neil
    Tolzien, Kathy
    Starr, Alexander
    BLOOD, 2010, 116 (21) : 737 - 738
  • [47] Contemporary treatment patterns and response in relapse/refractory cutaneous T-cell lymphoma (CTCL) in clinical practice in France, Germany Italy, Spain and the United Kingdom
    Illidge, T.
    Bagot, M.
    Waser, N.
    He, M.
    Li, T.
    Sambrook, R.
    Zomas, A.
    Trinchese, F.
    Gavini, F.
    Little, M.
    Ortiz, P.
    Pimpinelli, N.
    Dalal, M.
    Assaf, C.
    EUROPEAN JOURNAL OF CANCER, 2019, 119 : S36 - S36
  • [48] Phase 3 study of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A plus AVD) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) as front-line treatment for advanced classical Hodgkin lymphoma (HL): Echelon-1 study
    Ansell, Stephen Maxted
    Younes, Anas
    Connors, Joseph M.
    Gallamini, Andrea
    Kim, Won Seog
    Friedberg, Jonathan W.
    Feldman, Tatyana A.
    Collins, Graham
    Bartlett, Nancy
    Wang, Jingyuan
    Brady, Kelly
    Sachs, Jessica
    Huebner, Dirk
    Hunder, Naomi N. H.
    Radford, John
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [49] THE SWITCH FROM ABVD TO eBEACOPP AS FRONT-LINE THERAPY FOR HIGH-RISK STAGE III-IV CLASSICAL HODGKIN LYMPHOMA PATIENTS RESULTS IN AN INVERSION OF EVENT-FREE SURVIVAL OF PROGNOSTIC GROUPS
    Aurer, I.
    Basic-Kinda, S.
    Dujmovic, D.
    Radman, I.
    Dreta, B.
    Dotlic, S.
    Galunic-Bilic, L.
    Dobrenic, M.
    Kralik, M.
    Roncevic, P.
    HAEMATOLOGICA, 2016, 101 : 24 - 24
  • [50] Real-world treatment patterns in patients initiating third-line therapy for relapsed or refractory multiple myeloma in Germany, Italy, the United Kingdom, France, and Spain
    Lehne, Moritz
    Kortum, K. Martin
    Ramasamy, Karthik
    Zamagni, Elena
    d'Estrube, Tim
    Zhuleku, Evi
    Hanna, Maya
    Shukla, Soham
    Ghiani, Marco
    Maywald, Ulf
    Wilke, Thomas
    Kellermann, Lenka
    Perera, Sue
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2024, 112 (05) : 701 - 713
12345